|
US5580856A
(en)
|
1994-07-15 |
1996-12-03 |
Prestrelski; Steven J. |
Formulation of a reconstituted protein, and method and kit for the production thereof
|
|
ES2237767T3
(es)
|
1995-04-14 |
2005-08-01 |
Nektar Therapeutics |
Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
CA2226575C
(en)
|
1995-07-27 |
2011-10-18 |
Genentech, Inc. |
Stabile isotonic lyophilized protein formulation
|
|
JP3957765B2
(ja)
|
1997-04-07 |
2007-08-15 |
ジェネンテク・インコーポレイテッド |
抗ｖｅｇｆ抗体
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
AUPP494798A0
(en)
|
1998-07-29 |
1998-08-20 |
Pacific Biolink Pty Limited |
Protective protein formulation
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
CN100523187C
(zh)
|
1999-06-08 |
2009-08-05 |
里珍纳龙药品有限公司 |
具有改善的药物动力学特性的修饰嵌合多肽
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
US6833349B2
(en)
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US7306799B2
(en)
|
1999-06-08 |
2007-12-11 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF inhibitors for treatment of eye disorders
|
|
US7303746B2
(en)
|
1999-06-08 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with modified chimeric polypeptides
|
|
US6586574B1
(en)
|
1999-08-17 |
2003-07-01 |
Nn A/S |
Stabilization of freeze-dried cake
|
|
AU2002213441B2
(en)
|
2000-10-12 |
2006-10-26 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
CA2454587C
(en)
|
2001-07-25 |
2012-11-13 |
Protein Design Labs, Inc. |
Stable lyophilized pharmaceutical formulation of igg antibodies
|
|
AU2002335046A1
(en)
|
2001-10-19 |
2003-05-06 |
Inhale Therapeutic Systems, Inc. |
The use of proton sequestering agents in drug formulations
|
|
WO2003035028A1
(en)
|
2001-10-19 |
2003-05-01 |
Nektar Therapeutics |
Modulating charge density to produce improvements in the characteristics of spray-dried proteins
|
|
JP5290489B2
(ja)
|
2001-11-08 |
2013-09-18 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Ｉｇｇ抗体の安定な液体医薬製剤
|
|
PT1946776T
(pt)
|
2002-02-27 |
2017-03-17 |
Immunex Corp |
Composição de tnfr-fc estabilizada compreendendo arginina
|
|
CN1798575A
(zh)
|
2003-04-04 |
2006-07-05 |
健泰科生物技术公司 |
高浓度抗体和蛋白制剂
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US20050196340A1
(en)
|
2003-08-06 |
2005-09-08 |
Jocelyn Holash |
Use of a VEGF antagonist in combination with radiation therapy
|
|
CA2534197A1
(en)
|
2003-08-06 |
2005-02-24 |
Thomas Jefferson University |
Use of a vegf antagonist in combination with radiation therapy
|
|
NZ592039A
(en)
|
2003-08-27 |
2013-03-28 |
Ophthotech Corp |
Combination therapy for the treatment of ocular neovascular disorders
|
|
KR100897379B1
(ko)
|
2004-06-08 |
2009-05-14 |
쳉두 캉홍 바이오테크놀로지스 코. 리미티드 |
혈관신생-저해 키메릭 단백질 및 그 사용
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
PL1802334T3
(pl)
|
2004-10-21 |
2013-01-31 |
Genentech Inc |
Sposób leczenia wewnątrzgałkowych chorób neowaskularnych
|
|
CN102614134B
(zh)
|
2005-03-25 |
2016-09-07 |
瑞泽恩制药公司 |
Vegf拮抗剂制剂
|
|
MX2007015476A
(es)
|
2005-06-14 |
2008-02-25 |
Amgen Inc |
Formulaciones de proteina autoamortiguadoras.
|
|
ES2390354T3
(es)
|
2005-07-22 |
2012-11-12 |
Amgen, Inc |
Liofilizados de proteínas concentrados, procedimientos y usos
|
|
JP2009504571A
(ja)
|
2005-07-25 |
2009-02-05 |
トルービオン ファーマスーティカルズ インコーポレイテッド |
タンパク質解離のための組成物および方法
|
|
CN101312744A
(zh)
|
2005-11-22 |
2008-11-26 |
惠氏公司 |
免疫球蛋白融合蛋白制剂
|
|
BRPI0620316A2
(pt)
|
2005-12-21 |
2011-11-08 |
Wyeth Corp |
formulações de proteìnas com viscosidades reduzida e seus usos
|
|
FR2895258B1
(fr)
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
|
CA2638811A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
|
TW200806317A
(en)
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
|
CN100502945C
(zh)
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
|
US7608261B2
(en)
|
2006-06-16 |
2009-10-27 |
Regeneron Pharmacuticals, Inc. |
VEGF antagonist formulations suitable for intravitreal administration
|
|
WO2009015345A1
(en)
|
2007-07-25 |
2009-01-29 |
Amgen Inc. |
Pharmaceutical compositions comprising fc fusion proteins
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
ES2968301T3
(es)
|
2008-08-05 |
2024-05-08 |
Wyeth Llc |
Liofilización por encima del colapso
|
|
US8623395B2
(en)
|
2010-01-29 |
2014-01-07 |
Forsight Vision4, Inc. |
Implantable therapeutic device
|
|
AU2010263058A1
(en)
|
2009-06-18 |
2012-01-12 |
Wyeth Llc |
Lyophilized formulations for small modular immunopharmaceuticals
|
|
WO2010148321A1
(en)
|
2009-06-18 |
2010-12-23 |
Wyeth Llc |
Slow dissolution method for reconstitution of lyophilized material
|
|
CA2765220A1
(en)
|
2009-07-14 |
2011-01-20 |
Biogen Idec Ma Inc. |
Methods for inhibiting yellow color and peroxide formation in a composition
|
|
US20120121580A1
(en)
|
2009-07-28 |
2012-05-17 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
|
RU2012108108A
(ru)
|
2009-08-04 |
2013-09-10 |
Дженентек, Инк. |
Концентрированные полипептидные лекарственные формы с пониженной вязкостью
|
|
US20130029909A1
(en)
|
2009-09-15 |
2013-01-31 |
John Ryan |
Treatment of cancer
|
|
BR112012021576A2
(pt)
|
2010-02-26 |
2016-10-25 |
Novo Nordisk As |
composições estáveis contendo anticorpo.
|
|
US9956165B2
(en)
|
2010-03-01 |
2018-05-01 |
Cytodyn Inc. |
Concentrated protein formulations and uses thereof
|
|
KR20130060227A
(ko)
|
2010-05-03 |
2013-06-07 |
제넨테크, 인크. |
단백질-함유 제제의 점도 감소에 유용한 조성물 및 방법
|
|
EP2588138A1
(en)
|
2010-07-02 |
2013-05-08 |
Genentech, Inc. |
Treatment of vascularized pigment epithelial detachment with anti-vegf therapy
|
|
US20130274692A1
(en)
|
2010-08-05 |
2013-10-17 |
Yair Alster |
Subconjuctival implant for posterior segment drug delivery
|
|
CN103816115B
(zh)
*
|
2010-08-31 |
2017-06-27 |
成都康弘生物科技有限公司 |
一种含有抑制血管增生的融合蛋白的药物组合物及用途
|
|
CN102380096B
(zh)
|
2010-08-31 |
2014-04-30 |
成都康弘生物科技有限公司 |
一种含有抑制血管增生的融合蛋白的药物组合物及用途
|
|
KR20260004598A
(ko)
|
2011-01-13 |
2026-01-08 |
리제너론 파아마슈티컬스, 인크. |
혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
|
|
KR102081808B1
(ko)
|
2011-04-25 |
2020-02-26 |
아이콘 바이오사이언스, 인크. |
주사기용 투여량 가이드
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
US9574005B2
(en)
|
2011-07-19 |
2017-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stable Protein-containing preparation containing argininamide or analogous compound thereof
|
|
AU2012328524B2
(en)
|
2011-10-28 |
2017-05-18 |
Excelse Bio, Inc. |
Protein formulations containing amino acids
|
|
GB201122408D0
(en)
|
2011-12-23 |
2012-02-08 |
Univ Strathclyde |
Method for preparing dry protein formulations
|
|
AU2013212587B2
(en)
|
2012-01-23 |
2017-07-20 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-Ang2 antibodies
|
|
TWI775096B
(zh)
|
2012-05-15 |
2022-08-21 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
|
US20130323242A1
(en)
|
2012-06-01 |
2013-12-05 |
Ophthotech Corp. |
Compositions comprising an anti-pdgf aptamer and a vegf antagonist
|
|
LT3679922T
(lt)
|
2012-06-01 |
2021-10-25 |
Novartis Ag |
Švirkštas
|
|
AU2013267310A1
(en)
|
2012-06-01 |
2014-12-11 |
Ophthotech Corporation |
Compositions comprising an anti-PDGF aptamer and a VEGF antagonist
|
|
US20150150982A1
(en)
|
2012-06-12 |
2015-06-04 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical formulation for a therapeutic antibody
|
|
DE202013000688U1
(de)
|
2012-07-03 |
2013-03-05 |
Novartis Ag |
Glas-Spritze
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
EP2916827B1
(en)
|
2012-11-08 |
2020-06-10 |
Clearside Biomedical Inc. |
Methods for the treatment of ocular disease in human subjects
|
|
JP6026002B2
(ja)
|
2012-11-27 |
2016-11-16 |
アルテオジェン インコーポレイテッド |
タンパク質とＦｃドメインを融合した融合タンパク質の安定化用組成物
|
|
EP3744728A1
(en)
|
2013-02-12 |
2020-12-02 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
EP2994758B1
(en)
|
2013-05-08 |
2017-12-20 |
Opthea Limited |
Biomarkers for age-related macular degeneration (amd)
|
|
EP3003369A4
(en)
|
2013-05-28 |
2017-04-26 |
Momenta Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising pyrophosphate
|
|
MX375448B
(es)
|
2013-07-18 |
2025-03-06 |
Mannkind Corp |
Composiciones farmacéuticas en polvo seco estables al calor y métodos.
|
|
CA2927012A1
(en)
|
2013-11-05 |
2015-05-14 |
Allergan, Inc. |
Method of treating conditions of the eye with an anti-vegf darpin
|
|
RU2702748C2
(ru)
|
2014-05-12 |
2019-10-11 |
Формикон Аг |
Предварительно заполненный пластиковый шприц, содержащий антагонист vegf
|
|
US10478498B2
(en)
|
2014-06-20 |
2019-11-19 |
Reform Biologics, Llc |
Excipient compounds for biopolymer formulations
|
|
CA2952609A1
(en)
|
2014-06-26 |
2015-12-30 |
Amgen Inc. |
Solid protein formulations comprising stabilizer, sugar alcohol, sugar and surfactant
|
|
KR102486321B1
(ko)
|
2014-07-18 |
2023-01-09 |
사노피 |
암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
|
|
CN105435222B
(zh)
|
2014-09-25 |
2018-05-29 |
信达生物制药(苏州)有限公司 |
重组融合蛋白制剂
|
|
CN104940926B
(zh)
|
2014-09-25 |
2017-09-22 |
信达生物制药(苏州)有限公司 |
重组融合蛋白制剂
|
|
TWI738632B
(zh)
|
2014-11-07 |
2021-09-11 |
瑞士商諾華公司 |
穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
|
|
US20160144025A1
(en)
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
|
PT3230316T
(pt)
|
2014-12-11 |
2022-02-24 |
Bayer Healthcare Llc |
Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa
|
|
CN108348572B
(zh)
*
|
2015-03-31 |
2021-06-29 |
日东制药株式会社 |
含有融合组织穿透肽和抗-vegf制剂的融合蛋白的预防和治疗眼疾的药物组合物
|
|
PH12017501857B1
(en)
|
2015-06-16 |
2024-01-17 |
Merck Patent Gmbh |
Pd-l1 antagonist combination treatments
|
|
KR101808234B1
(ko)
*
|
2015-06-23 |
2017-12-12 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
|
|
AU2016297178A1
(en)
|
2015-07-22 |
2018-01-25 |
Iconic Therapeutics, Inc. |
Methods for treating disorders associated with angiogenesis and neovascularization
|
|
US20230134160A1
(en)
|
2015-09-22 |
2023-05-04 |
Pfizer Inc. |
Method Of Preparing A Therapeutic Protein Formulation And Antibody Formulation Produced By Such A Method
|
|
RU2763916C2
(ru)
|
2015-09-23 |
2022-01-11 |
Дженентек, Инк. |
Оптимизированные варианты анти-vegf антител
|
|
WO2017066554A1
(en)
|
2015-10-16 |
2017-04-20 |
Regeneron Pharmaceuticals, Inc. |
Stable protein compositions
|
|
WO2017075252A1
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibody variant conjugates and uses thereof
|
|
CN108290004A
(zh)
|
2015-11-18 |
2018-07-17 |
福尔密孔股份公司 |
含有vegf拮抗剂的预填充塑料注射器
|
|
WO2017087798A1
(en)
|
2015-11-18 |
2017-05-26 |
Formycon Ag |
Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
|
|
JP2018535242A
(ja)
|
2015-11-30 |
2018-11-29 |
メディミューン，エルエルシー |
高濃度のタンパク質ベースの治療剤を含有する医薬組成物中の非晶質安定化化合物としてのアミノ酸と糖との最適比
|
|
PT3384049T
(pt)
|
2015-12-03 |
2023-08-18 |
Regeneron Pharma |
Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
|
|
CN108778330A
(zh)
*
|
2016-01-08 |
2018-11-09 |
科尼尔赛德生物医学公司 |
用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置
|
|
JP6942135B2
(ja)
|
2016-01-25 |
2021-09-29 |
サノフイＳａｎｏｆｉ |
血漿バイオマーカーのレベルを測定することによる、がんに罹患していることが疑われる患者のアフリベルセプトによる治療の転帰を予測するための方法
|
|
AU2017213103B2
(en)
|
2016-01-26 |
2022-08-11 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
US20190060241A1
(en)
|
2016-04-13 |
2019-02-28 |
Medimmune, Llc |
Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
|
|
DK3471780T3
(da)
|
2016-06-16 |
2020-11-23 |
Adverum Biotechnologies Inc |
Behandling af amd med aav2-variant med aflibercept
|
|
WO2018013673A1
(en)
|
2016-07-13 |
2018-01-18 |
Reform Biologics, Llc |
Stabilizing excipients for therapeutic protein formulations
|
|
SG11201901081XA
(en)
|
2016-08-17 |
2019-03-28 |
Boehringer Ingelheim Int |
Process for the preparation of highly concentrated liquid formulations containing biomolecules
|
|
DK3500856T3
(da)
|
2016-08-18 |
2020-12-14 |
Regeneron Pharma |
Assay til bestemmelse af et proteins potentiale for at selvassociere ved hjælp af koncentrationsafhængig selvinteraktionsnanopartikelspektroskopi
|
|
AU2017317129B2
(en)
|
2016-08-24 |
2020-04-30 |
National Institute Of Biological Sciences, Beijing |
Entacapone-related compounds to treat macular degeneration
|
|
CA3038894A1
(en)
|
2016-09-28 |
2018-04-05 |
Board Of Regents, The University Of Texas System |
Antibody and protein therapeutic formulations and uses thereof
|
|
CA3039655A1
(en)
|
2016-10-07 |
2018-04-12 |
Regeneron Pharmaceuticals, Inc. |
Room temperature stable lyophilized protein
|
|
CN109937034B
(zh)
|
2016-11-21 |
2022-09-16 |
济世-伊沃泰克生物制品有限公司 |
阿柏西普制剂及其用途
|
|
EP3549608A4
(en)
|
2016-12-01 |
2020-08-12 |
Jiangsu Hengrui Medicine Co., Ltd. |
USE OF A COMBINATION OF A VEGFR INHIBITOR AND PARP INHIBITOR IN THE MANUFACTURING OF A MEDICINAL PRODUCT FOR TREATMENT OF STOMACH CANCER
|
|
US11123411B2
(en)
|
2016-12-08 |
2021-09-21 |
Gary E. Borodic |
Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
|
|
US20200368331A1
(en)
|
2016-12-08 |
2020-11-26 |
Gary E. Borodic |
Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals
|
|
CR20190291A
(es)
|
2016-12-23 |
2019-11-05 |
Serum Institute Of India Pvt Ltd |
Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos
|
|
US10617756B2
(en)
|
2017-01-05 |
2020-04-14 |
Shimojani, LLC |
Drug regimen for treatment of cerebral ischemia
|
|
US10426817B2
(en)
|
2017-01-24 |
2019-10-01 |
Macregen, Inc. |
Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
|
|
KR101861163B1
(ko)
|
2017-04-26 |
2018-05-25 |
삼천당제약주식회사 |
안과용 약학 조성물
|
|
AU2018258654B2
(en)
|
2017-04-27 |
2022-01-06 |
The Johns Hopkins University |
Dendrimer compositions for use in angiography
|
|
CA3063324A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
US20200108064A1
(en)
|
2017-06-08 |
2020-04-09 |
Eye Therapies, Llc |
Low-dose brimonidine combinations and uses thereof
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
AU2018306303A1
(en)
|
2017-07-25 |
2020-02-20 |
Elektrofi, Inc. |
Formation of particles including agents
|
|
WO2019020777A1
(en)
*
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
WO2019036619A1
(en)
|
2017-08-18 |
2019-02-21 |
Reform Biologics, Llc |
STABILIZING EXCIPIENTS FOR FORMULATIONS OF THERAPEUTIC PROTEIN
|
|
IT201700101582A1
(it)
|
2017-09-12 |
2019-03-12 |
Milano Politecnico |
Dispositivo per rilascio intraoculare
|
|
IL272513B2
(en)
|
2017-09-15 |
2023-04-01 |
Amgen Inc |
Lyophilization process for pharmaceutical formulation of medical protein
|
|
MA50174A
(fr)
|
2017-09-18 |
2020-07-29 |
Amgen Inc |
Formules de protéines de fusion vegfr-fc
|
|
WO2019066603A1
(ko)
|
2017-09-29 |
2019-04-04 |
한미약품 주식회사 |
효력이 향상된 지속성 단백질 결합체
|
|
US11246846B2
(en)
|
2017-10-23 |
2022-02-15 |
Michael S. Tempesta |
Trisodium citrate compositions having enhanced uptake across digestive mucosa
|
|
WO2019099786A1
(en)
|
2017-11-16 |
2019-05-23 |
Ophthotech Corporation |
A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (ipcv)
|
|
JP7536640B2
(ja)
|
2017-11-17 |
2024-08-20 |
アムジエン・インコーポレーテツド |
ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤
|
|
CA3081094A1
(en)
|
2017-11-20 |
2019-05-23 |
Alison J. GILLESPIE |
Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
|
|
EP4122486A1
(en)
|
2017-11-30 |
2023-01-25 |
Regeneron Pharmaceuticals, Inc. |
Use of a vegf antagonist to treat diabetic retinopathy
|
|
CA3080644A1
(en)
|
2017-12-06 |
2019-06-13 |
Quanren WANG |
Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
|
|
KR102742284B1
(ko)
*
|
2017-12-22 |
2024-12-16 |
삼성바이오에피스 주식회사 |
Vegf 길항제를 포함하는 액상 조성물
|
|
FI3743091T3
(fi)
|
2018-01-26 |
2025-01-03 |
Univ California |
Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita
|
|
US11426446B2
(en)
|
2018-03-08 |
2022-08-30 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
EP3761953A1
(en)
|
2018-03-08 |
2021-01-13 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
KR102791798B1
(ko)
|
2018-04-12 |
2025-04-07 |
암젠 인크 |
안정한 단백질 조성물의 제조 방법
|
|
WO2019212211A1
(en)
|
2018-04-30 |
2019-11-07 |
Gachon University Of Industry-Academic Cooperation Foundation |
Antiangiogenic chromane derivative and uses thereof
|
|
CN108671229B
(zh)
|
2018-05-08 |
2022-03-25 |
华博生物医药技术（上海）有限公司 |
一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
|
|
US11103552B2
(en)
|
2018-05-10 |
2021-08-31 |
Regeneron Pharmaceuticals, Inc. |
High concentration VEGF receptor fusion protein containing formulations
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
TW202011995A
(zh)
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
|
WO2020055123A1
(ko)
|
2018-09-10 |
2020-03-19 |
삼성바이오에피스 주식회사 |
단백질을 포함하는 액상 조성물
|
|
EP3636657A1
(en)
|
2018-10-08 |
2020-04-15 |
Ablynx N.V. |
Chromatography-free antibody purification method
|
|
WO2020087003A1
(en)
|
2018-10-26 |
2020-04-30 |
Amgen Inc. |
Formulations comprising a tris buffer and a protein
|
|
CN110664757B
(zh)
|
2018-11-19 |
2022-08-02 |
成都瑞沐生物医药科技有限公司 |
纳米晶滴眼剂、其制备方法及其应用
|
|
WO2020106948A1
(en)
|
2018-11-21 |
2020-05-28 |
Regeneron Pharmaceuticals, Inc. |
High concentration protein formulation
|
|
CA3122227A1
(fr)
|
2018-12-20 |
2020-06-25 |
Laboratoires Thea |
Composition ophtalmique nutraceutique pour le traitement de pathologies retiniennes a composante neovasculaire
|
|
CA3127228A1
(en)
|
2019-01-30 |
2020-08-06 |
Amgen Inc. |
Aflibercept attributes and methods of characterizing and modifying thereof
|
|
JP7663501B2
(ja)
|
2019-02-11 |
2025-04-16 |
スロゼン オペレーティング， インコーポレイテッド |
眼障害におけるｗｎｔシグナル伝達の調節
|
|
CN113710228A
(zh)
|
2019-02-13 |
2021-11-26 |
诺瓦利克有限责任公司 |
用于治疗眼部新生血管形成的组合物和方法
|
|
WO2020255135A1
(en)
|
2019-06-17 |
2020-12-24 |
Sol-Gel Technologies Ltd. |
Treatment of ocular inflammatory diseases with topical ophthalmic tapinarof compositions
|
|
US20200390725A1
(en)
|
2019-06-17 |
2020-12-17 |
Sol-Gel Technologies Ltd. |
Treatment of ocular diseases with ophthalmic tapinarof compositions
|
|
US20200390724A1
(en)
|
2019-06-17 |
2020-12-17 |
Sol-Gel Technologies Ltd. |
Treatment of ocular diseases with ophthalmic tapinarof compositions
|
|
MY204342A
(en)
|
2019-03-25 |
2024-08-24 |
Alteogen Inc |
Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
|
|
BR112021019612A2
(pt)
|
2019-04-01 |
2021-11-30 |
Genentech Inc |
Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
|
|
US20220184186A1
(en)
|
2019-04-03 |
2022-06-16 |
Denali Therapeutics Inc. |
Formulations of protein molecules comprising iduronate 2-sulfatase
|
|
US12599669B2
(en)
|
2019-04-23 |
2026-04-14 |
Amgen Inc. |
Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations
|
|
EP3736574A1
(en)
|
2019-05-07 |
2020-11-11 |
Atlas Antibodies AB |
A formulation comprising an isotope labeled fusion polypeptide
|
|
TW202110454A
(zh)
|
2019-05-30 |
2021-03-16 |
大陸商江蘇恒瑞醫藥股份有限公司 |
Cdk4/6抑制劑與vegfr抑制劑聯合在製備治療腫瘤的藥物中的用途
|
|
KR20220034169A
(ko)
|
2019-07-10 |
2022-03-17 |
리제너론 파아마슈티컬스, 인크. |
감소된 수준의 숙주 세포 단백질을 포함하는 방법 및 조성물
|
|
CA3145239A1
(en)
|
2019-08-06 |
2021-02-11 |
Hugh LIN |
Personalized treatment of ophthalmologic diseases
|
|
US20210100856A1
(en)
|
2019-09-11 |
2021-04-08 |
Adverum Biotechnologies, Inc. |
Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
|
|
AU2020345174A1
(en)
|
2019-09-12 |
2022-03-31 |
Lupin Limited |
Modified dosing of VEGF inhibitors for ophthalmic use
|
|
US20220340630A1
(en)
|
2019-09-13 |
2022-10-27 |
National Science And Technology Development Agency |
Composition of renaturation buffer solution for dimeric proteins and method of renaturation dimeric proteins using the composition thereof
|
|
CA3154653A1
(en)
|
2019-09-17 |
2021-03-25 |
Merck Patent Gmbh |
Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
|
|
AU2020384917A1
(en)
|
2019-11-15 |
2022-03-31 |
F. Hoffmann-La Roche Ag |
Prevention of visible particle formation in aqueous protein solutions
|
|
US20230355544A1
(en)
|
2019-12-03 |
2023-11-09 |
Sichuan Honghe Biotechnology Co., Ltd |
Pharmaceutical Composition Containing Elemene, Preparation Method Therefor, And Use Thereof
|
|
AU2020397053A1
(en)
|
2019-12-06 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
VEGF mini-traps and methods of use thereof
|
|
US11180540B2
(en)
|
2019-12-06 |
2021-11-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-VEGF protein compositions and methods for producing the same
|
|
WO2021125852A1
(ko)
|
2019-12-17 |
2021-06-24 |
주식회사 프로젠 |
신규 주사제 제형
|
|
CN115279406A
(zh)
|
2020-01-13 |
2022-11-01 |
阿帕特夫研究和发展有限公司 |
蛋白质治疗剂的调配物
|
|
WO2021168218A1
(en)
|
2020-02-19 |
2021-08-26 |
Clearside Biomedical, Inc. |
Compositions comprising axitinib and methods of treating ocular disorders
|
|
EP3884929B1
(en)
|
2020-03-25 |
2023-06-14 |
Ocular Therapeutix, Inc. |
Ocular implant containing a tyrosine kinase inhibitor
|
|
CN115279405B
(zh)
|
2020-04-10 |
2025-02-18 |
江苏恒瑞医药股份有限公司 |
一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途
|
|
US20230272041A1
(en)
|
2020-04-22 |
2023-08-31 |
Dragonfly Therapeutics, Inc. |
Formulation, Dosage Regimen, and Manufacturing Process for Heterodimeric FC-Fused Proteins
|
|
AU2021287906B2
(en)
|
2020-06-11 |
2025-09-11 |
Alkahest Inc. |
Methods of improving retina-associated disease outcome using CCR3-inhibitors
|
|
US11944663B2
(en)
|
2020-06-18 |
2024-04-02 |
Chengdu Kanghong Biotechnologies Co. Ltd. |
Method for treating angiogenic eye disorders using VEGF antagonists
|
|
EP4178530A1
(en)
|
2020-07-09 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Concentrated compositions of proteins, their preparation and use thereof
|
|
WO2022011323A1
(en)
|
2020-07-10 |
2022-01-13 |
Iconic Therapeutics, Inc. |
Ocular disease treatment using anti-tissue factor antibodies
|
|
MX2023000557A
(es)
|
2020-07-13 |
2023-02-13 |
Merck Patent Gmbh |
Excipientes reductores de la viscosidad y combinaciones de los mismos para formulaciones proteicas altamente concentradas.
|
|
PH12023550015A1
(en)
|
2020-07-16 |
2024-03-11 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
EP4188384A1
(en)
|
2020-07-29 |
2023-06-07 |
Seagen Inc. |
Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist
|
|
US20230312683A1
(en)
|
2020-07-31 |
2023-10-05 |
Celltrion Inc. |
Stable pharmaceutical preparation
|
|
DE102020005002A1
(de)
|
2020-08-17 |
2022-02-17 |
Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh |
Mittel zur Therapie von Tumorerkrankungen
|
|
WO2022056326A1
(en)
|
2020-09-11 |
2022-03-17 |
Elixir Medical Corporation |
Anticoagulant compounds, methods and devices for ophthalmic use
|
|
EP4236986A1
(en)
|
2020-10-30 |
2023-09-06 |
Gemini Therapeutics Sub, Inc. |
Methods for treating inflammatory ocular diseases with complement factor h
|
|
MX2023004839A
(es)
|
2020-10-30 |
2023-06-29 |
Eluminex Biosciences Suzhou Ltd |
Inhibidores de factores angiogenicos.
|
|
JP2023549776A
(ja)
|
2020-11-13 |
2023-11-29 |
アストラゼネカ・ユーケイ・リミテッド |
医薬製剤
|
|
CA3197627A1
(en)
|
2020-11-18 |
2022-05-27 |
Kimberly SHEPARD |
Inhalable dry powder formulations comprising angiogenesis inhibitors
|
|
FI20215186A1
(en)
|
2021-02-19 |
2022-08-20 |
Rebio Tech Oy |
Compositions for ophthalmic treatment
|
|
US20240156907A1
(en)
|
2021-03-16 |
2024-05-16 |
Kashiv Biosciences, Llc |
Novel formulation of fusion protein
|
|
WO2022201084A1
(en)
|
2021-03-26 |
2022-09-29 |
Novartis Ag |
Methods for treating ocular diseases
|
|
CA3210368A1
(en)
|
2021-04-09 |
2022-10-13 |
Shengjiang Liu |
Compositions and methods for ocular transgene expression
|
|
JP2024515459A
(ja)
|
2021-04-27 |
2024-04-10 |
アドヴェラム バイオテクノロジーズ， インコーポレイテッド |
アフリベルセプトをコードするａａｖ２バリアントを使用する眼疾患の治療方法
|
|
WO2022229932A1
(en)
|
2021-04-29 |
2022-11-03 |
Einar Stefansson |
Hypoxia inducible factor (hif) inhibitors for treatment of atrophy associated with retinal hypoxia
|
|
IL308505A
(en)
|
2021-05-17 |
2024-01-01 |
Regeneron Pharma |
Continuous high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders
|
|
WO2023001288A1
(zh)
|
2021-07-23 |
2023-01-26 |
百奥泰生物制药股份有限公司 |
整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用
|
|
US20240358855A1
(en)
|
2021-08-18 |
2024-10-31 |
University Of Utah Research Foundation |
Multigene constructs for treatment of age-related macular degeneration and other complement dysregulation-related conditions
|
|
EP4398877A1
(en)
|
2021-09-06 |
2024-07-17 |
LEK Pharmaceuticals d.d. |
Formulations for vegf receptor fusion proteins
|
|
EP4147709A1
(en)
|
2021-09-14 |
2023-03-15 |
The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth |
A composition comprising il-36 and/or il-18 for use in treating ocular disorders
|
|
EP4424301A4
(en)
|
2021-10-29 |
2025-11-19 |
Alteogen Inc |
Pharmaceutical composition comprising a human PH20 hyaluronidase and a medicinal product
|